{"id":3844,"date":"2024-06-07T15:47:15","date_gmt":"2024-06-07T08:47:15","guid":{"rendered":"https:\/\/thaipropertynews.com\/feeds\/?p=3844"},"modified":"2024-06-07T15:47:15","modified_gmt":"2024-06-07T08:47:15","slug":"mlb-announces-ind-approval-by-us-fda-to-initiate-phase-1-trial-of-tml-6-a-new-era-multi-target-drug-for-the-treatment-of-alzheimers-disease","status":"publish","type":"post","link":"https:\/\/thaipropertynews.com\/feeds\/?p=3844","title":{"rendered":"MLB Announces IND Approval by US FDA to Initiate Phase 1 Trial of TML-6, a New Era Multi-Target Drug for the Treatment of Alzheimer’s Disease"},"content":{"rendered":"

TAINAN, June 7, 2024<\/span> \/PRNewswire\/ — MLB (Merry Life Biomedical Company, Ltd., Taiwan<\/span>: https:\/\/www.tmlbio.com\/<\/a>), a biomedical company, announced that the U.S. Food and Drug Administration (FDA) has approved IND application for TML-6, an novel drug to treat Alzheimer’s disease (AD), enabling a Phase 1 clinical trial to be initiated this July. Advancing TML-6 into clinical trial is a critical milestone for MLB to develop a new era multi-target drug for AD since 2018.<\/p>\n

\n

<\/a>
<\/span><\/p>\n<\/div>\n

About TML-6<\/p>\n

TML-6\u00a0is a novel synthetic curcumin analog. Professor Ih-Jen Su<\/span> at Southern Taiwan<\/span> University used a platform of 6 aging and AD biomarkers to screen the 12 compounds from Androscience (San Diego<\/span>, USA<\/span>) for AD candidate. Preclinical studies showed that TML-6 (ASC-6) exhibits a multi-target action mechanism for AD, including anti-aging, activation of autophagy (mTOR inhibitor), reducing amyloid accumulation, and anti-inflammation (Figure 1), the efficacy confirmed by 2 AD animal models. TML-6 has a high bioavailability through formulation and then completed preclinical toxicology and safety studies. TML-6 should be potentially a novel drug to improve or reverse the progression of early-stage AD.<\/p>\n

The Design and Future Plan of TML-6 for AD Clinical Trials<\/p>\n

TML-6\u00a0is developed as an oral drug and will conduct a SAD\/MAD phase 1 clinical trial at Glendale Adventist Medical Center, LA, USA in 2024 Q3. Elderly cohort and CSF pharmacokinetics (PK) studies were specifically designed. For a global multi-site phase 2a clinical trial, several distinguished global AD experts provided consultation. Blood biomarkers will be included in the phase 2a trial as the surrogate endpoint of efficacy. Furthermore, TML-6 is considering to combine with the current anti-amyloid drugs in phase 2 trial. The drug combination could not only exhibit synergistic effects to improve AD behavior, reducing amyloid accumulation and ant-inflammation, but can also reduce antibody dosing to only 10% and avoid the adverse events (ARIAs) of anti-body drugs. MLB has successfully raised funds to conduct this global phase 2a clinical trial, scheduled to be conducted on 2025 Q3.<\/p>\n

Contact:
Chien Hong Lin<\/span>, PhD
Email: rd07@tmlbio.com<\/a><\/p>\n

<\/div>","protected":false},"excerpt":{"rendered":"

<\/p>\n

TAINAN, June 7, 2024<\/span> \/PRNewswire\/ — MLB (Merry Life Biomedical Company, Ltd., Taiwan<\/span>: https:\/\/www.tmlbio.com\/<\/a>), a biomedical company, announced that the U.S. Food and Drug Administration (FDA) has approved IND application for TML-6, an novel drug to treat Alzheimer’s disease (AD), enabling a Phase 1 clinical trial to be initiated this July. Advancing TML-6 into clinical trial is a critical milestone for MLB to develop a new era multi-target drug for AD since 2018.<\/p>\n

\n

<\/a>
<\/span><\/p>\n<\/div>\n

About TML-6<\/p>\n

TML-6\u00a0is a novel synthetic curcumin analog. Professor Ih-Jen Su<\/span> at Southern Taiwan<\/span> University used a platform of 6 aging and AD biomarkers to screen the 12 compounds from Androscience (San Diego<\/span>, USA<\/span>) for AD candidate. Preclinical studies showed that TML-6 (ASC-6) exhibits a multi-target action mechanism for AD, including anti-aging, activation of autophagy (mTOR inhibitor), reducing amyloid accumulation, and anti-inflammation (Figure 1), the efficacy confirmed by 2 AD animal models. TML-6 has a high bioavailability through formulation and then completed preclinical toxicology and safety studies. TML-6 should be potentially a novel drug to improve or reverse the progression of early-stage AD.<\/p>\n

The Design and Future Plan of TML-6 for AD Clinical Trials<\/p>\n

TML-6\u00a0is developed as an oral drug and will conduct a SAD\/MAD phase 1 clinical trial at Glendale Adventist Medical Center, LA, USA in 2024 Q3. Elderly cohort and CSF pharmacokinetics (PK) studies were specifically designed. For a global multi-site phase 2a clinical trial, several distinguished global AD experts provided consultation. Blood biomarkers will be included in the phase 2a trial as the surrogate endpoint of efficacy. Furthermore, TML-6 is considering to combine with the current anti-amyloid drugs in phase 2 trial. The drug combination could not only exhibit synergistic effects to improve AD behavior, reducing amyloid accumulation and ant-inflammation, but can also reduce antibody dosing to only 10% and avoid the adverse events (ARIAs) of anti-body drugs. MLB has successfully raised funds to conduct this global phase 2a clinical trial, scheduled to be conducted on 2025 Q3.<\/p>\n

Contact:
Chien Hong Lin<\/span>, PhD
Email: rd07@tmlbio.com<\/a><\/p>\n

<\/div>\n

<\/p>\n","protected":false},"author":0,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":[],"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[5,7],"tags":[],"class_list":["post-3844","post","type-post","status-publish","format-standard","hentry","category-cision-pr-newswire","category-cision-pr-newswire-en"],"_links":{"self":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts\/3844","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/types\/post"}],"replies":[{"embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=3844"}],"version-history":[{"count":0,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts\/3844\/revisions"}],"wp:attachment":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=3844"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=3844"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=3844"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}